GoodRx Holdings, Inc.
GDRX · Price history
Price at last available close
$3.48
+$0.17 (+5.14%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About GoodRx Holdings, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States.
How they make money
GoodRx operates a digital healthcare platform that generates revenue primarily through prescription transaction fees paid by pharmacy benefit managers when consumers use GoodRx codes to purchase medications. Additionally, the company earns revenue from pharmaceutical manufacturers through advertising and data solutions, as well as from subscription services and telehealth offerings.
Products & services
GoodRx provides a digital platform for prescription drug price comparison, telehealth services, and pharmaceutical manufacturer solutions, including advertising and patient support programs.
Brands & revenue mix
The primary consumer-facing brand for prescription savings and healthcare information.
Separate brand revenue is not available in this research.Source
The company's internal telehealth provider brand.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
The company discloses that its business is subject to significant concentration in the U.S. healthcare market, particularly regarding its reliance on PBMs and pharmacy networks.
Suppliers, materials & equipment
- Pharmacy Benefit Managers (PBMs) — PBMs provide the negotiated pricing networks that enable the GoodRx prescription savings platform.Source
Strengths
- Leading platform for medication savings in the U.S.Source
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
34
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
49
Weak
Financial Strength
66
Business Quality / Moat
59
Management
42
Growth Quality
24
Risk / Durability
25
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
24
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
34/100
Building Historical Record
Model Score 34/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for GDRX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving GDRX's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is GDRX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does GDRX's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What future growth or profitability would be needed to justify GDRX's current valuation?
Essential Investment Snapshot
Wall Street Score
34
Opportunity Score
24
Market Cap
$1.19B
P/E Ratio
62.5
EPS
$0.05
52-Week High
$5.81
52-Week Low
$1.77
Beta
1.60
Intrinsic Value
$0.58
Analyst Target
$4.00
Shares Outstanding
357.0M
Total Revenue
$785.2M
Total Debt
$539.0M
Dividend
No current dividend
Liquidation Value / Share
$1.81
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for GDRX
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on GDRX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Leading platform for medication savings in the U.S.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Healthcare Information Services industry.
- −Dependence on PBMs and pharmacy networks.
- −Regulatory pressures in the healthcare and pharmaceutical industries.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
34
Sep 24, 2026
Change
Unchanged
Current Score
34
Oct 1, 2026
Category Changes
GDRX score was unchanged.
Projected Score
Projected Score
33
Projected Change
-0.6 points
Preliminary comparable-period financial changes suggest decline of approximately 0.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$3.48
Model Intrinsic Value
$0.58
Difference
+$2.90
+496.0% vs IV
Margin of Safety
-496.0%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $785.2M | $796.9M | $792.3M | $750.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $93.8M | $57.6M | $48.2M | $66.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $691.4M | $739.3M | $744.1M | $683.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $116.8M | $121.0M | $123.7M | $135.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $432.8M | $445.5M | $485.0M | $466.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $610.9M | $651.8M | $678.3M | $710.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $148.6M | $184.4M | $153.9M | $108.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $80.5M | $87.5M | $65.8M | -$27.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $40.8M | $42.6M | $52.9M | $56.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $41.4M | $56.5M | $31.5M | -$55.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $25.1M | $26.1M | $15.1M | -$46.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $16.2M | $30.4M | $16.4M | -$8.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $0.05 | $0.09 | $0.04 | $-0.02 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 339M | 356M | 386M | 410M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 348M | 357M | 392M | 410M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$200.4M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.02
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-1.6%
Cash Change
+5.3%
Margin Change
-2.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included revenue growth, EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 1.3%. EPS declined 44.4%. Cash increased 5.3%. Total debt declined 1.6%. Net income margin declined by 2.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Healthcare Information ServicesNews
Amazon, GoodRx target US prescription subscribers as health insurance coverage slips
GoodRx Covers Whole Households and Pets in New Prescription Plan
GoodRx offers health subscription for families, to launch as employee benefit in 2027
From Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household
Rumor Mill · GDRX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial